Biomarkers for gastric cancer: Progression in early diagnosis and prognosis (review)

Oncology Letters

Volumn 9, Issue 4, 2015, Pages 1502-1508

  Jin, Ziliang ^a   Jiang, Weihua ^a   Wang, Liwei ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Biological marker; Early diagnosis; Gastric cancer; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CADHERIN; CARCINOEMBRYONIC ANTIGEN; CYCLIN E; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAS LIGAND; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLYCOPROTEIN GP 130; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 6; MICRORNA; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN BAX; PROTEIN P53; RHO KINASE; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR SOX17; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR NECROSIS FACTOR; VASCULOTROPIN; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 3;

ADJUVANT CHEMOTHERAPY; ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE; DNA METHYLATION; DNA REPLICATION; DOWN REGULATION; EARLY DIAGNOSIS; EPIGENETICS; GENE OVEREXPRESSION; HUMAN; LIVER METASTASIS; MICROSATELLITE INSTABILITY; MRNA EXPRESSION ASSAY; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TUMOR GROWTH; UPREGULATION;

EID: 84923172302     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.2959     Document Type: Article

References (111)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Hu B, El Hajj N, Sittler S, et al: Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol 3: 251-261, 2012.
3. Nitti D, Mocellin S, Marchet A, Pilati P and Lise M: Recent advances in conventional and molecular prognostic factors for gastric carcinoma. Surg Oncol Clin N Am 17: 467-483, 2008.
4. Resende C, Ristimäki A and Machado JC: Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter 15: 34-39, 2010.
5. Pectasides D, Mylonakis A, Kostopoulou M, et al: CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. Am J Clin Oncol 20: 348-353, 1997.
6. Wu WK, Lee CW, Cho CH, et al: MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene 29: 5761-5771, 2010.
7. Ye T, Chen Y and Fang J: DNA methylation biomarkers in serum for gastric cancer screening, Mini Rev Med Chem 10: 1034-1038, 2010.
8. Lu J, Huang CM, Zheng CH, et al: Prognostic value of tumor size in patients with remnant gastric cancer: Is the seventh UICC stage sufficient for predicting prognosis? PloS One 9: e115776, 2014.
9. Gold P and Freedman SO: Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122: 467-481, 1965.
10. Tatsuta M, Itoh T, Okuda S, et al: Carcinoembryonic antigen in gastric juice as an aid in diagnosis of early gastric cancer. Cancer 46: 2686-2692, 1980.
11. Szymendera JJ: Clinical usefulness of three monoclonal antibody-defined tumor markers: CA 19-9, CA 50, and CA 125. Tumour Biol 7: 333-342, 1986.
12. Tsukamoto Y, Nakada C, Noguchi T, et al: MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 70: 2339-2349, 2010.
13. Oh HK, Tan AL, Das K, et al: Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res 17: 2657-2667, 2011.
14. Katada T, Ishiguro H, Kuwabara Y, et al: microRNA expression profile in undifferentiated gastric cancer. Int J Oncol 34: 537-542, 2009.
15. Ueda T, Volinia S, Okumura H, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 11: 136-146, 2010.
16. Song JH and Meltzer SJ: MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology 143: 35-47.e2, 2012.
17. He XP, Shao Y, Li XL, et al: Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J 279: 4201-4212, 2012.
18. Wang M, Li C, Nie H, et al: Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. FEBS Lett 586: 2382-2388, 2012.
19. Yamanaka S, Olaru AV, An F, et al: MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer. Dig Liver Dis 44: 589-596, 2012.
20. Cao W, Fan R, Wang L, et al: Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells. Tumour Biol 34: 963-971, 2013.
21. Crone SG, Jacobsen A, Federspiel B, et al: microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-κB by targeting CARD10 and COPS8 in gastric cancer. Mol Cancer 11: 71, 2012.
22. Sacconi A, Biagioni F, Canu V, et al: miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis 3: e423, 2012.
23. Xu Y, Zhao F, Wang Z, et al: MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene 31: 1398-1407, 2012.
24. Cai H, Yuan Y, Hao YF, et al: Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol 30: 452, 2013.
25. Zhang X, Cui L, Ye G, et al: Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumour Biol 33: 2349-2355, 2012.
26. Yu X, Luo L, Wu Y, et al: Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Med Oncol 30: 365, 2013.
27. Compare D, Rocco A, Liguori E, et al: Global DNA hypomethylation is an early event in Helicobacter pylori-related gastric carcinogenesis. J Clin Pathol 64: 677-682, 2011.
28. Oishi Y, Watanabe Y, Yoshida Y, et al: Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer. Tumour Biol 33: 383-393, 2012.
29. Hudler P: Genetic aspects of gastric cancer instability. ScientificWorldJournal 2012: 761909, 2012.
30. Ling ZQ, Tanaka A, Li P, et al: Microsatellite instability with promoter methylation and silencing of hMLH1 can regionally occur during progression of gastric carcinoma. Cancer Lett 297: 244-251, 2010.
31. Ohue M, Tomita N, Monden T, et al: Mutations of the transforming growth factor beta type II receptor gene and microsatellite instability in gastric cancer. Int J Cancer 68: 203-206, 1996.
32. Iacopetta BJ, Soong R, House AK and Hamelin R: Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF-beta type II receptor, IGFII receptor, and BAX genes. J Pathol 187: 428-432, 1999.
33. Fleisher AS, Esteller M, Wang S, et al: Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 59: 1090-1095, 1999.
34. Choi SW, Choi JR, Chung YJ, et al: Prognostic implications of microsatellite genotypes in gastric carcinoma. Int J Cancer 89: 378-383, 2000.
35. Wirtz HC, Müller W, Noguchi T, et al: Prognostic value and clinicopathological profile of microsatellite instability in gastric cancer. Clin Cancer Res 4: 1749-1754, 1998.
36. dos Santos NR, Seruca R, Constância M, et al: Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology 110: 38-44, 1996.
37. Yasui W, Sumiyoshi H, Hata J, et al: Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 48: 137-141, 1988.
38. Sakai K, Mori S, Kawamoto T, et al: Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 77: 1047-1052, 1986.
39. García I, Vizoso F, Martín A, et al: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10: 234-241, 2003.
40. Terashima M, Kitada K, Ochiai A, et al; ACTS-GC Group: Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 18: 5992-6000, 2012.
41. Zhou F, Li N, Jiang W, et al: Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. World J Surg Oncol 10: 274, 2012.
42. Kim JY, Jeon TJ, Bae BN, et al: The prognostic significance of growth factors and growth factor receptors in gastric adenocarcinoma. APMIS 121: 95-104, 2013.
43. Ye YW, Zhang X, Zhou Y, et al: The correlations between the expression of FGFR4 protein and clinicopathological parameters as well as prognosis of gastric cancer patients. J Surg Oncol 106: 872-879, 2012.
44. Amemiya H, Kono K, Itakura J, et al: c-Met expression in gastric cancer with liver metastasis. Oncology 63: 286-296, 2002.
45. Graziano F, Galluccio N, Lorenzini P, et al: Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29: 4789-4795, 2011.
46. Warnecke-Eberz U, Bollschweiler E, Drebber U, et al: Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer. Anticancer Res 29: 4451-4455, 2009.
47. Ishigami S, Natsugoe S, Okumura H, et al: Clinical implication of CXCL12 expression in gastric cancer. Ann Surg Oncol 14: 3154-3158, 2007.
48. Kim DK, Oh SY, Kwon HC, et al: Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 9: 155, 2009.
49. Liao WC, Lin JT, Wu CY, et al: Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res 14: 428-434, 2008.
50. Nagashima N, Nakayama Y, Inoue Y, et al: Prognostic significance of the local expression of interleukin-12 in patients with advanced gastric cancer. Anticancer Res 28: 1277-1283, 2008.
51. Ashizawa T, Okada R, Suzuki Y, et al: Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 8: 124-131, 2005.
52. Graziano F, Ruzzo A, Santini D, et al: Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer. J Clin Oncol 23: 2339-2345, 2005.
53. Macrì A, Versaci A, Loddo S, et al: Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. Biomarkers 11: 184-193, 2006.
54. Necula LG, Chivu-Economescu M, Stanciulescu EL, et al: IL-6 and IL-11 as markers for tumor aggressiveness and prognosis in gastric adenocarcinoma patients without mutations in Gp130 subunits. J Gastrointestin Liver Dis 21: 23-29, 2012.
55. Lin MT, Lin BR, Chang CC, et al: IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer 120: 2600-2608, 2007.
56. Lee JH, Cho YS, Lee JY, et al: The chemokine receptor CCR4 is expressed and associated with a poor prognosis in patients with gastric cancer. Ann Surg 249: 933-941, 2009.
57. Al-Moundhri MS, Nirmala V, Al-Hadabi I, et al: The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients. J Surg Oncol 91: 243-252, 2005.
58. Tenderenda M: A study on the prognostic value of cyclins D1 and E expression levels in resectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes. J Exp Clin Cancer Res 24: 405-414, 2005.
59. Nitti D, Belluco C, Mammano E, et al: Low level of p27(Kip1) protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. J Surg Oncol 81: 167-175; discussion 175-166, 2002.
60. Xiangming C, Natsugoe S, Takao S, et al: The cooperative role of p27 with cyclin E in the prognosis of advanced gastric carcinoma. Cancer 89: 1214-1219, 2000.
61. Sgambato A, Migaldi M, Leocata P, et al: Loss of p27Kip1 expression is a strong independent prognostic factor of reduced survival in N0 gastric carcinomas. Cancer 89: 2247-2257, 2000.
62. Ichiyoshi Y, Oiwa H, Tomisaki S, et al: Overexpression of p53 is associated with growth pattern and prognosis in advanced gastric cancer. Hepatogastroenterology 44: 546-553, 1997.
63. Gonçalves AR, Carneiro AJ, Martins I, et al: Prognostic significance of p53 protein expression in early gastric cancer. Pathol Oncol Res 17: 349-355, 2011.
64. Feakins RM, Nickols CD, Bidd H and Walton SJ: Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol 34: 1276-1282, 2003.
65. Aurello P, Bellagamba R, Rossi Del Monte S, et al: Apoptosis and microvessel density in gastric cancer: correlation with tumor stage and prognosis. Am Surg 75: 1183-1188, 2009.
66. Koshida Y, Saegusa M and Okayasu I: Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer 75: 367-373, 1997.
67. Inada T, Kikuyama S, Ichikawa A, et al: Bcl-2 expression as a prognostic factor of survival of gastric carcinoma. Anticancer Res 18: 2003-2010, 1998.
68. Aizawa K, Ueki K, Suzuki S, et al: Apoptosis and Bbcl-2 expression in gastric carcinomas: correlation with clinicopathological variables, p53 expression, cell proliferation and prognosis. Int J Oncol 14: 85-91, 1999.
69. Osaki M, Kase S, Kodani I, et al: Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis. Gastric Cancer 4: 198-205, 2001.
70. Nagashima H, Mori M, Sadanaga N, et al: Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis. Int J Oncol 18: 1157-1162, 2001.
71. Liu X, Cai H, Huang H, et al: The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients. PLoS One 6: e29670, 2011.
72. Lee HK, Lee HS, Yang HK, et al: Prognostic significance of Bcl-2 and p53 expression in gastric cancer. Int J Colorectal Dis 18: 518-525, 2003.
73. Kim MA, Lee HE, Lee HS, et al: Expression of apoptosis-related proteins and its clinical implication in surgically resected gastric carcinoma. Virchows Arch 459: 503-510, 2011.
74. Komatsu S, Ichikawa D, Tsujiura M, et al: Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res 33: 271-276, 2013.
75. Cui L, Zhang X, Ye G, et al: Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer. Cancer 119: 1618-1626, 2013.
76. Liu JL, Gao W, Kang QM, et al: Prognostic value of survivin in patients with gastric cancer: a systematic review with meta-analysis. PLoS One 8: e71930, 2013.
77. Okada E, Murai Y, Matsui K, et al: Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 163: 109-116, 2001.
78. Song KY, Jung CK, Park WS and Park CH: Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma. Jpn J Clin Oncol 39: 290-296, 2009.
79. Kim BH, Hong SW, Kim A, et al: Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol 107: 505-510, 2013.
80. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, et al: Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med 10: 186, 2012.
81. Cheng AS, Li MS, Kang W, et al: Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis. Gastroenterology 144: 122-133.e9, 2013.
82. Yu QM, Wang XB, Luo J, et al: CDH1 methylation in preoperative peritoneal washes is an independent prognostic factor for gastric cancer. J Surg Oncol 106: 765-771, 2012.
83. Park SJ, Jang HR, Kim M, et al: Epigenetic alteration of CCDC67 and its tumor suppressor function in gastric cancer. Carcinogenesis 33: 1494-1501, 2012.
84. Negrini M, Miotto E, Sabbioni S, et al: MINT31 methylation in gastric noninvasive neoplasia: potential role in the secondary prevention of gastric cancer. Eur J Cancer Prev 21: 442-448, 2012.
85. Hu SL, Kong XY, Cheng ZD, et al: Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma. Tumori 96: 726-733, 2010.
86. Huang FY, Chan AO, Rashid A, et al: Helicobacter pylori induces promoter methylation of E-cadherin via interleukin-1β activation of nitric oxide production in gastric cancer cells. Cancer 118: 4969-4980, 2012.
87. Wani M, Afroze D, Makhdoomi M, et al: Promoter methylation status of DNA repair gene (hMLH1) in gastric carcinoma patients of the Kashmir valley. Asian Pac J Cancer Prev 13: 4177-4181, 2012.
88. Hibi K, Sakata M, Yokomizi K, et al: Methylation of the WNT5A gene is frequently detected in early gastric carcinoma. Hepatogastroenterology 59: 2661-2663, 2012.
89. Guo W, Dong Z, Guo Y, et al: Aberrant methylation and loss expression of RKIP is associated with tumor progression and poor prognosis in gastric cardia adenocarcinoma. Clin Exp Metastasis 30: 265-275, 2013.
90. Wang XH, Zhang LH, Zhong XY, et al: S100A6 overexpression is associated with poor prognosis and is epigenetically up-regulated in gastric cancer. Am J Pathol 177: 586-597, 2010.
91. Sugita H, Iida S, Inokuchi M, et al: Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol Rep 25: 513-518, 2011.
92. Li X, Cheung KF, Ma X, et al: Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients. Oncogene 31: 3419-3430, 2012.
93. Zhan Z, Wu J, Zhang JF, et al: CDH1 gene polymorphisms, plasma CDH1 levels and risk of gastric cancer in a Chinese population. Mol Biol Rep 39: 8107-8113, 2012.
94. Yuan LJ, Jin TB, Yin JK, et al: Polymorphisms of tumor-related genes IL-10, PSCA, MTRR and NOC3 L are associated with the risk of gastric cancer in the Chinese Han population. Cancer Epidemiol 36: e366-e372, 2012.
95. Xue H, Lu Y, Lin B, et al: The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis. PLoS One 7: e43431, 2012.
96. Tian J, Pan F, Li J, et al: Association between the FAS/FASL polymorphisms and gastric cancer risk: a meta-analysis. Asian Pac J Cancer Prev 13: 945-951, 2012.
97. Ozen A, Kocak Z, Sipahi T, et al: The prognostic significance of p21 and Her-2 gene expression and mutation/polymorphism in patients with gastric adenocarcinoma. Med Oncol 30: 357, 2013.
98. Lu R, Gao X, Chen Y, et al: Association of an NFKB1 intron SNP (rs4648068) with gastric cancer patients in the Han Chinese population. BMC Gastroenterol 12: 87, 2012.
99. He J, Xu Y, Qiu LX, et al: Polymorphisms in ERCC1 and XPF genes and risk of gastric cancer in an eastern Chinese population. PLoS One 7: e49308, 2012.
100. Han L, Lee SW, Yoon JH, et al: Association of SOD1 and SOD2 single nucleotide polymorphisms with susceptibility to gastric cancer in a Korean population. APMIS 121: 246-256, 2013.
101. Han F, Wang X, Wang X, Luo Y and Li W: Meta-analysis of the association of CYP1A1 polymorphisms with gastric cancer susceptibility and interaction with tobacco smoking. Mol Biol Rep 39: 8335-8344, 2012.
102. Zhang XP, Bai ZB, Chen BA, et al: Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. Chin Med J (Engl) 125: 741-746, 2012.
103. Oh SY, Kwon HC, Kim SH, et al: The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer 13: 43, 2013.
104. Liu B, Wei J, Zou Z, et al: Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 15: 1049-1053, 2007.
105. Li QF, Yao RY, Liu KW, et al: Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. J Korean Med Sci 25: 846-852, 2010.
106. Kim JG, Sohn SK, Chae YS, et al: TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol 64: 355-360, 2009.
107. Shirai O, Ohmiya N, Taguchi A, et al: P53, p21, and p73 gene polymorphisms in gastric carcinoma. Hepatogastroenterology 57: 1595-1601, 2010.
108. Wang S, Chen L, Zhao Q, et al: Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy. Cancer Chemother Pharmacol 71: 1073-1082, 2013.
109. García-González MA, Nicolás-Pérez D, Lanas A, et al: Prognostic role of host cyclooxygenase and cytokine genotypes in a Caucasian cohort of patients with gastric adenocarcinoma. PLoS One 7: e46179, 2012.
110. Liu J, Song B, Wang JL, et al: Polymorphisms of interleukin-10 promoter are not associated with prognosis of advanced gastric cancer. World J Gastroenterol 17: 1362-1367, 2011.
111. Tahara T, Shibata T, Nakamura M, et al: Effect of IL-1β and TNF-α polymorphisms on the prognosis and survival of gastric cancer patients. Clin Exp Med 11: 211-217, 2011.